Bayer Schering inks Singapore cancer research pact
This article was originally published in Scrip
Bayer Schering Pharma (BSP) is to collaborate with the National University of Singapore to conduct preclinical research in oncology. The deal is the second between a pharma multinational and the island state's national research facilities in the past few months.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.